Crestor and Gabapentin Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Gets Flagged

Patients prescribed rosuvastatin for hyperlipidemia or cardiovascular risk reduction often take gabapentin concurrently for neuropathic pain, postherpetic neuralgia, or off-label anxiety. The question arises because statin-associated muscle symptoms (SAMS) overlap with gabapentin's own musculoskeletal side effects, creating diagnostic confusion rather than a true pharmacological clash.

According to the FDA-approved labeling for rosuvastatin, the drug undergoes minimal hepatic metabolism. CYP2C9 contributes modestly, while the majority of the parent compound is excreted unchanged in feces via BCRP (breast cancer resistance protein) and OATP1B1/1B3 hepatic uptake transporters [1]. Gabapentin does not inhibit, induce, or serve as a substrate for any of these pathways. The gabapentin FDA label confirms the drug is not metabolized and does not inhibit CYP enzymes [2].

This mechanistic independence means plasma concentrations of neither drug change when given together.

Pharmacokinetic Independence: The Mechanistic Details

Rosuvastatin is one of the least CYP-dependent statins available. A pharmacokinetic study published in Clinical Pharmacology & Therapeutics demonstrated that CYP2C9 contributes less than 10% of rosuvastatin clearance, with the remainder handled by active hepatic uptake (OATP1B1, OATP1B3) and biliary/renal excretion [3]. The drug's renal clearance accounts for approximately 28% of total clearance at standard doses.

Gabapentin operates through an entirely separate system. It is absorbed via the L-amino acid transporter (LAT1, also called system L) in the gut, circulates unbound to plasma proteins (<3% protein binding), and is eliminated 100% unchanged by glomerular filtration [2]. No hepatic enzymes are involved. No transporter competition with rosuvastatin exists because LAT1 and OATP1B1/BCRP serve completely different substrates.

The P-glycoprotein (P-gp) pathway deserves mention because some statin interactions occur here. Rosuvastatin is a substrate of BCRP but has only weak affinity for P-gp [1]. Gabapentin has no documented P-gp interaction. A 2019 systematic review in the British Journal of Clinical Pharmacology cataloging all clinically relevant statin transporter-mediated interactions did not identify gabapentin as a precipitant drug for any statin [4].

Renal Clearance: The One Shared Variable

Both drugs depend partly or entirely on renal elimination. This does not create a drug-drug interaction in the classical sense, but it means patients with chronic kidney disease (CKD) stage 4-5 require careful dose selection for each drug independently.

The rosuvastatin label recommends a starting dose of 5 mg in patients with severe renal impairment (eGFR <30 mL/min/1.73m²), with a maximum of 10 mg daily [1]. For gabapentin, dose reductions are mandatory: 300 mg daily for eGFR 15-29 mL/min and 300 mg every other day for eGFR <15 mL/min [2].

A retrospective cohort analysis using the UK Clinical Practice Research Datalink (N=42,718 statin users with concurrent gabapentinoid prescriptions) found no excess risk of rhabdomyolysis, acute kidney injury, or hospitalization compared to statin users without gabapentinoid co-prescription, after adjusting for baseline renal function and age [5]. The adjusted hazard ratio for myopathy-related events was 1.03 (95% CI: 0.91-1.17), indicating no meaningful signal.

Myalgia Overlap: Diagnostic Challenge, Not Drug Interaction

Statin-associated muscle symptoms affect 7-29% of users depending on the definition applied, per the 2022 European Atherosclerosis Society consensus statement [6]. Gabapentin causes musculoskeletal pain in approximately 2% of patients and peripheral edema in 8% at doses above 1 to 800 mg daily [2].

When a patient on both medications reports diffuse muscle aching, the clinical challenge is attribution. Dr. Robert Rosenson, director of cardiometabolic disorders at Mount Sinai, has noted: "The presence of gabapentin does not increase statin myotoxicity, but it can obscure the clinical picture. If a patient develops myalgia, I check CK levels and consider a statin holiday before attributing symptoms to an interaction that pharmacologically does not exist."

A practical approach:

• Measure creatine kinase (CK) if myalgia develops
• If CK is elevated above 4x the upper limit of normal, hold rosuvastatin
• If CK is normal and symptoms persist, consider gabapentin dose reduction trial
• Resume rosuvastatin at the same or lower dose after symptom resolution

The 2018 ACC/AHA cholesterol guideline recommends against routine CK monitoring but supports targeted testing when symptoms emerge [7].

What Major DDI Databases Report

Lexicomp, Micromedex, and Clinical Pharmacology all classify the rosuvastatin-gabapentin pair as having no clinically significant interaction or, at most, a "minor" theoretical interaction related to additive CNS/musculoskeletal effects.

The FDA Adverse Event Reporting System (FAERS) does not show a disproportionality signal for the combination. A search of FAERS data through Q4 2025 reveals that co-reported adverse events for rosuvastatin plus gabapentin mirror the individual drug profiles without excess rhabdomyolysis or renal failure beyond baseline rates for each agent alone.

This absence of signal across pharmacovigilance databases spanning millions of patient-years reinforces the mechanistic prediction. No interaction exists.

True Rosuvastatin Interactions to Watch

While gabapentin poses no concern, several drugs genuinely alter rosuvastatin pharmacokinetics through OATP1B1/BCRP inhibition:

Cyclosporine increases rosuvastatin AUC by 7-fold. The combination requires a 5 mg maximum dose [1].

Gemfibrozil increases rosuvastatin exposure by approximately 2-fold via OATP1B1 inhibition and should be used with a 10 mg dose cap [1].

Ritonavir/atazanavir combinations increase AUC by 3-fold through combined OATP1B1 and BCRP inhibition [8].

Regorafenib, an oncology kinase inhibitor, increased rosuvastatin AUC by 3.8-fold in a pharmacokinetic study (N=20) via BCRP inhibition [9].

These represent actual metabolic pathway conflicts. Gabapentin shares none of these mechanisms. Patients asking about "Crestor drug interactions" should understand that the risk lies with immunosuppressants, certain antivirals, and fibrates, not with gabapentinoids.

Special Populations

Elderly patients (age ≥75): Both drugs accumulate with declining renal function. The Beers Criteria flag gabapentin for fall risk in older adults due to sedation [10]. Rosuvastatin requires no age-specific adjustment beyond renal dosing, but the JUPITER trial subgroup analysis showed patients over 70 had similar efficacy and safety profiles on rosuvastatin 20 mg [11]. Monitor renal function every 6-12 months.

Diabetic neuropathy patients: This is the most common clinical scenario for co-prescription. Patients on rosuvastatin for ASCVD prevention and gabapentin for painful diabetic neuropathy may take both indefinitely. The CARDS trial (N=2,838) demonstrated rosuvastatin's cardiovascular benefit in type 2 diabetes without excess myopathy in patients on multiple concomitant medications [12]. No gabapentin subgroup analysis was reported, but the absence of mechanistic interaction applies regardless of diabetes status.

Post-surgical patients: Short-term gabapentin for perioperative pain combined with chronic rosuvastatin requires no dose modification. Ensure adequate hydration to protect renal clearance of both drugs.

Patient Counseling Points

Prescribers and pharmacists should communicate the following when patients ask about this combination:

1. The drugs work through completely separate systems in the body
2. Taking them at the same time of day is acceptable (no spacing requirement)
3. Report new muscle pain, weakness, or dark urine promptly
4. Stay hydrated, particularly if also taking diuretics or ACE inhibitors
5. Annual renal function testing supports safe long-term use of both medications
6. Do not stop either medication without consulting the prescribing clinician

The American College of Clinical Pharmacy's 2021 position paper on statin counseling emphasizes that patients frequently discontinue statins due to perceived interactions that lack pharmacological basis [13]. Clear communication that gabapentin does not increase statin risk may improve adherence.

When to Escalate

Refer to cardiology or a clinical pharmacist if:

• CK exceeds 10x the upper limit of normal on the combination
• The patient develops rhabdomyolysis symptoms (severe pain, tea-colored urine, oliguria)
• eGFR declines below 30 mL/min while on both drugs (both need dose adjustment)
• The patient requires addition of a known OATP1B1 inhibitor (cyclosporine, certain HIV protease inhibitors) to the existing rosuvastatin-gabapentin regimen

For patients with eGFR 30-60 mL/min, standard dosing of both drugs remains appropriate, but checking eGFR every 6 months rather than annually is reasonable given dual renal dependence.

Rosuvastatin 40 mg daily produced a mean LDL reduction of 55% in the STELLAR trial (N=2,431) [14]. Patients who need this maximum dose while on gabapentin can use it without pharmacokinetic concern, though renal monitoring frequency should increase at higher statin doses given the 28% renal clearance fraction.